AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06516523 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PEMF and Control/Sham
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation) Use of PEMF on experimental implants (Bone-to-implant contact)
Study NCT06516523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEMF and Control/Sham
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation) Use of PEMF on experimental implants (Bone-to-implant contact)
Study NCT06516523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEMF and Control/Sham
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation) Use of PEMF on experimental implants (Bone-to-implant contact)
Study NCT06516523 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PEMF and without PEMF
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation)
Study NCT06516523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEMF and without PEMF
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation)
Study NCT06516523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF and without PEMF
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation)
Study NCT06444191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Rilzabrutinib tablet(s) administered orally
Study NCT06155396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: 2.0 mg/kg IV every 2 weeks
Study NCT06155396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: 240mg IV every 2 weeks
Study NCT06252324 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prime taper implant + cover screw
Description: tissue level implant placement with the addition of a cover screw
Study NCT06252324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prime taper implant + healing screw
Description: bone level implant placement with the addition of a healing screw
Study NCT05094700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-marketed Cosmetic Facial Cleanser
Description: Participants will apply non-marketed cosmetic facial cleanser on cleanse facial skin, twice daily for 4 weeks.
Study NCT00446602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: Type=exact, unit=units, number=80,000, form=solution for injection, route=subcutaneous use, once every week or once every 2 weeks.
Study NCT05586269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal Kit Delivery
Description: Families receive 6 weeks of healthy meal kit delivery. Meal kits come with embedded nutrition education and access to online cooking demonstrations.
Study NCT06042517 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HEC - Hyperinsulinemic-Euglycemic-Clamp
Description: A constant i.v. insulin and variable glucose infusion will be used to determine insulin sensitivity of study participants.
Study NCT04743102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multi-points and full-thickness Biopsy
Description: Four points around the tumor site and center of the tumor site full-thickness Biopsy
Study NCT04743102 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: traditional cCR
Description: diginal examination, endoscopy test, rectal MRI, and serum CEA level
Study NCT05639907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K21 Cavity cleanser
Description: K21 Cavity cleanser is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
Study NCT05639907 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol control
Description: Ethanol is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
Study NCT05289635 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: different suture types
Description: For a wound that is deeper in nature, a mattress stitch can be placed, providing better strength. Mattress sutures can be applied as vertical or horizontal subtypes. So far, various studies have compared the effect of horizontal mattress suture (HMS) with vertical mattress suture (VMS) on wound healing in different wound. However, limited studies have evaluated the effect of the subtype of mattress sutures on the early wound healing and microcirculation changes of peri-implant soft tissues following implant surgery using Laser Doppler flowmetry. The test group use vertical mattress suture and the control group use the horizontal mattress suture.
Study NCT05289635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different suture types
Description: For a wound that is deeper in nature, a mattress stitch can be placed, providing better strength. Mattress sutures can be applied as vertical or horizontal subtypes. So far, various studies have compared the effect of horizontal mattress suture (HMS) with vertical mattress suture (VMS) on wound healing in different wound. However, limited studies have evaluated the effect of the subtype of mattress sutures on the early wound healing and microcirculation changes of peri-implant soft tissues following implant surgery using Laser Doppler flowmetry. The test group use vertical mattress suture and the control group use the horizontal mattress suture.
Study NCT05243706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Intervention is given to study its' effect on vinca alkaloids induced neuropathy
Study NCT05243706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin/ Hesperidin
Description: Intervention is given to study its effect on vinca alkaloids induced neuropathy
Study NCT05345340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Polar Vantage M devices will collect the objective measurement after the 5-day rehabilitation program (for five consecutive days), week 12 (for five consecutive days), and week 24 (for five consecutive days).
Study NCT05345340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
Study NCT04990804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Analgesic
Description: Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
Study NCT04990804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid-Free Postoperative Pain Regimen
Description: Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
Study NCT05000827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSMA-PET/CT
Description: In the intervention arm patients will only undergo ePLND in addition to robot-assisted radical prostatectomy (RARP) in case of suspected LNI on PSMA PET/CT (miN1), whereas ePLND will be omitted in those without PSMA positive lymph nodes (miN0).
Study NCT05000827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nomogram
Description: Current standard of care includes performing extended pelvic lymph node dissection (ePLND) in all patients with primary prostate cancer and a nomogram-based risk of LNI >5%
Study NCT04841889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Associated factors with decannulation
Description: All factors potentially associated with successful tracheostomy removal will be prospectively collected: severity factors related to the ICU stay, ventilatory factors, respiratory and extra-respiratory factors. Lung and diaphragm ultrasound, swallowing, muscles and functional assessment will be performed.
Study NCT06524661 — intervention group
Intervention type: DEVICE
Intervention: AS-OCT after vitrectomy
Description: AS-OCT is a light based imaging technique of the anterior segment of the eye in this study it is used to measure the anterior chamber angle changes after pars plana vitrectomy.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biochemistry blood test
Description: preformed on days 1-14 and day 28. Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL,
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Biochemistry blood test
Description: preformed on days 1-14 and day 28. Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL,
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hematology blood test
Description: preformed on days 1-14 and day 28. complete CBC.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hematology blood test
Description: preformed on days 1-14 and day 28. complete CBC.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: D-Dimer test (coagulation)
Description: performed on days 1,2,7,14 and 28.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: D-Dimer test (coagulation)
Description: performed on days 1,2,7,14 and 28.
Study NCT04611399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR for psychoeducation and relaxation
Description: Use of specifically developed VR contents to deliver psychoeducational content on stress and anxiety (i.e., MIND-VR) and to train on relaxation techniques (i.e., The Secret Garden).
Study NCT04611399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (CR)
Description: The CR Group will undergo pre- and post-protocol tests without undergoing any treatment.
Study NCT06278441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care and White noise
Description: CG newborns underwent routine heel lancing, and no intervention was performed.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Description: performed on days 1-7, 14 and 28. IL-6, IL-1β, IL-12, TNF α, IFN-γ
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Inflammatory markers
Description: performed on days 1-7, 14 and 28. IL-6, IL-1β, IL-12, TNF α, IFN-γ
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital signs
Description: performed on days 1-14 and day 28. blood pressure, pulse, weight, weight, body temperature (PO), saturation, respiratory rate.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Vital signs
Description: performed on days 1-14 and day 28. blood pressure, pulse, weight, weight, body temperature (PO), saturation, respiratory rate.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAS scale
Description: performed on all study visits. score: 0-10 ; a higher score indicates a higher pain level.
Study NCT03595995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-621
Description: Monoclonal antibody by SC injection
Study NCT03595995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is a sterile, clear and colorless or slightly yellow liquid, contains the same composition as UB-621 except drug substance. It is given by SC injection.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: VAS scale
Description: performed on all study visits. score: 0-10 ; a higher score indicates a higher pain level.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WHO Ordinal Score
Description: performed on days 1,7,14 and 28. score: 0-3 ; a higher score indicates more symptoms.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: WHO Ordinal Score
Description: performed on days 1,7,14 and 28. score: 0-3 ; a higher score indicates more symptoms.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19-Related Symptoms assessment
Description: performed on days 1,7,14,21 and 28. score: 0-3 ; a higher score indicates more symptoms.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19-Related Symptoms assessment
Description: performed on days 1,7,14,21 and 28. score: 0-3 ; a higher score indicates more symptoms.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19-Impact on Quality-of-Life Questionnaire
Description: performed on days 1,7,14,21 and 28. score: 1-5 ; a higher score indicates a lower quality of life.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19-Impact on Quality-of-Life Questionnaire
Description: performed on days 1,7,14,21 and 28. score: 1-5 ; a higher score indicates a lower quality of life.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POST- COVID-19 Functional Status Scale:
Description: performed on day 28. score: 0-3 ; a higher score indicates better recovery.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: POST- COVID-19 Functional Status Scale:
Description: performed on day 28. score: 0-3 ; a higher score indicates better recovery.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: performed on days 1 and 28. women of childbearing potential must undergo a urine pregnancy test.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Pregnancy test
Description: performed on days 1 and 28. women of childbearing potential must undergo a urine pregnancy test.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical examination
Description: performed on days 1-14 and day 28. a full examination by a doctor.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Physical examination
Description: performed on days 1-14 and day 28. a full examination by a doctor.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PK parameters
Description: performed on day 1. will be performed only on 14 patients that will agree to participate in the PK analysis (only for Brazil,Spain).~The PK will be performed only for the first dose of drug, after patient received the first dose (5 puffs) the study staff need to follow the table below.~For each test, approximately 5 ml of blood will be drawn (equivalent to one teaspoon)
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: PK parameters
Description: performed on day 1. will be performed only on 14 patients that will agree to participate in the PK analysis (only for Brazil,Spain).~The PK will be performed only for the first dose of drug, after patient received the first dose (5 puffs) the study staff need to follow the table below.~For each test, approximately 5 ml of blood will be drawn (equivalent to one teaspoon)
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 test (PCR)
Description: performed on days 1,14 and 28.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: SARS-CoV-2 test (PCR)
Description: performed on days 1,14 and 28.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: performed on days 1 and 28.
Study NCT06089551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmofKabiven
Description: Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.
Study NCT06089551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SmofKabiven
Description: Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.
Study NCT05037162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: ECG
Description: performed on days 1 and 28.
Study NCT05037162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment administration (twice a day)
Description: performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)
Study NCT05037162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment administration (twice a day)
Description: performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)
Study NCT05500755 — intervention group
Intervention type: DEVICE
Intervention: Implant Treatment
Description: Surgical placement of a DS Prime Taper implant and its posterior prosthesis.
Study NCT05240690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Derived MAK Immune Cells
Description: Intravenous drip
Study NCT05447494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose CAN103
Description: Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations.
Study NCT05447494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose CAN103
Description: Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations.
Study NCT04716790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Debridement
Description: Ultrasounds debridement is performed using an SONOCA 185 device (Söring GmbH, Germany). The ultrasounds device generates an ultrasound low frequency of 25kHz and is equipped with three instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth. The ultrasounds instrument piezoelectrically transforms the electrical energy delivered from the ultrasound device into mechanical oscillations in the sonotrode tip.
Study NCT04716790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Conventional Treatment based on international guidelines for diabetic foot